Ocular Therapeutix/$OCUL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ticker
$OCUL
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
274
ISIN
US67576A1007
Website
OCUL Metrics
BasicAdvanced
$1.5B
-
-$1.15
1.50
-
Price and volume
Market cap
$1.5B
Beta
1.5
52-week high
$11.26
52-week low
$5.79
Average daily volume
2.4M
Financial strength
Current ratio
10.222
Quick ratio
9.885
Long term debt to equity
27.852
Total debt to equity
28.663
Interest coverage (TTM)
-16.44%
Profitability
EBITDA (TTM)
-201.834
Gross margin (TTM)
-160.40%
Net profit margin (TTM)
-323.09%
Operating margin (TTM)
-344.83%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-27.21%
Return on equity (TTM)
-57.19%
Valuation
Price to revenue (TTM)
25.824
Price to book
5.5
Price to tangible book (TTM)
5.5
Price to free cash flow (TTM)
-10.378
Free cash flow yield (TTM)
-9.64%
Free cash flow per share (TTM)
-88.56%
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
-11.49%
3-year revenue growth (CAGR)
6.51%
10-year revenue growth (CAGR)
48.15%
3-year earnings per share growth (CAGR)
4.20%
10-year earnings per share growth (CAGR)
-4.96%
What the Analysts think about OCUL
Analyst ratings (Buy, Hold, Sell) for Ocular Therapeutix stock.
Bulls say / Bears say
Ocular Therapeutix has secured a $325 million private placement, providing substantial capital to advance its clinical programs, particularly the Phase 3 trials for AXPAXLI targeting wet age-related macular degeneration (AMD). (biospace.com)
The company has achieved alignment with the FDA on the SOL-R trial design for AXPAXLI, reducing regulatory uncertainties and potentially accelerating the path to market approval. (markets.businessinsider.com)
Ocular Therapeutix has strengthened its leadership team by appointing Dr. Pravin U. Dugel as Executive Chairman and other key executives, aiming to enhance its position in retinal care. (investing.com)
In Q1 2025, Ocular Therapeutix reported a 27.6% decline in total net revenue to $10.7 million, primarily due to reduced DEXTENZA sales, indicating potential challenges in product commercialization. (tradingview.com)
The company reported a net loss of $64.1 million in Q1 2025, with research and development expenses increasing significantly to $42.9 million, reflecting high costs associated with ongoing clinical trials. (tradingview.com)
Ocular Therapeutix faces competition from established players like Regeneron, whose eye drug Eylea continues to perform strongly, potentially impacting market share for new entrants. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
OCUL Financial Performance
Revenues and expenses
OCUL Earnings Performance
Company profitability
OCUL News
AllArticlesVideos
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
GlobeNewsWire·6 hours ago
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
GlobeNewsWire·2 weeks ago
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocular Therapeutix stock?
Ocular Therapeutix (OCUL) has a market cap of $1.5B as of June 26, 2025.
What is the P/E ratio for Ocular Therapeutix stock?
The price to earnings (P/E) ratio for Ocular Therapeutix (OCUL) stock is 0 as of June 26, 2025.
Does Ocular Therapeutix stock pay dividends?
No, Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Ocular Therapeutix dividend payment date?
Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocular Therapeutix?
Ocular Therapeutix (OCUL) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.